Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5860089 | 0.87 | ALDH1A1 (0.49) | CSF1RPOLBMEN1MAPTKMT2A | |
| SCHEMBL5859825 | 0.78 | LMNA (0.50) | LMNAL3MBTL1MAPTALDH1A1KDM4E | |
| SCHEMBL6431346 | 0.77 | MAPT (0.51) | CSF1RMEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL14492310 | 0.76 | KDM4E (0.57) | LMNAL3MBTL1MTNR1AMTNR1BPOLB | |
| SCHEMBL5860177 | 0.76 | MAPT (0.44) | LMNAL3MBTL1MTNR1AMTNR1BMEN1 | |
| SCHEMBL11383772 | 0.76 | KDM4E (0.57) | LMNAL3MBTL1POLBMEN1KMT2A | |
| SCHEMBL7986686 | 0.75 | MAPT (0.41) | LMNAL3MBTL1MTNR1AMTNR1BMEN1 | |
| SCHEMBL4376884 | 0.74 | MTNR1A (0.61) | LMNAL3MBTL1MTNR1AMTNR1BMEN1 | |
| SCHEMBL8121796 | 0.73 | TUBB4A (0.58) | LMNAL3MBTL1CSF1RMEN1KMT2A | |
| SCHEMBL6626098 | 0.72 | GRIN2D (0.47) | LMNACSF1RMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135478-B2 | Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2006-11-14 | — | — | US | disclosed |
| US-7053102-B2 | Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2006-05-30 | — | — | US | disclosed |
| US-20050038064-A1 | Anticarcinogenic agents; breast, colon, lung, prostate, ovarian, and gastric cancers, leukemia, melanomas; (5R)-5-ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2005-02-17 | — | — | US | disclosed |
| US-20040254163-A1 | New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2004-12-16 | — | — | US | disclosed |
| US-6815546-B2 | ANTICANCER AGENTS | SOCIETE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-11-09 | — | — | US | disclosed |
| US-6797715-B1 | Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-09-28 | — | — | US | disclosed |
| US-6762301-B2 | Analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-13 | — | — | US | disclosed |
| US-20030004150-A1 | New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | IPSEN PHARMA S.A.S. (FR) | 2003-01-02 | — | — | US | disclosed |
| US-20020160994-A1 | New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2002-10-31 | — | — | US | disclosed |
| US-6339091-B1 | USEFUL IN THERAPY OF OF VIRAL INFECTIONS, PARASITIC DISEASES AND CANCER | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254163-A1 | New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | TOP2A, TOP1, MCL1 | LMNA 857/4885L3MBTL1 3308/4885MTNR1A 3226/4885 |
| US-20030004150-A1 | New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | TOP1, TOP2A, TYMP | LMNA 846/4885L3MBTL1 3438/4885MTNR1A 3000/4885 |
| US-20050038064-A1 | Anticarcinogenic agents; breast, colon, lung, prostate, ovarian, and gastric cancers, leukemia, melanomas; (5R)-5-ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione | MCL1, BRCA1, API5 | LMNA 2019/4885L3MBTL1 511/4885MTNR1A 30/4885 |
| US-20020160994-A1 | New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them | TOP2A, TOP1, TOP2B | LMNA 957/4885L3MBTL1 4208/4885MTNR1A 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.